MT is a fifty-six-year-old obese (BMI 31.5) Caucasian female…
Introduction:
Hypertension and dyslipidemia are common cardiovascular risk factors that contribute to the development of cardiovascular disease (CVD). Managing these conditions is essential to reduce the risk of adverse cardiovascular events. In the case of MT, a 56-year-old obese Caucasian female with a significant family history of CVD, it is crucial to review her current medications for hypertension and dyslipidemia and evaluate their efficacy in addressing her specific needs, taking into consideration her age, gender, and ethnicity. This paper will provide an analysis of MT’s medications, discuss potential changes, provide justifications for these changes, and highlight patient teaching and lifestyle alterations that could benefit her.
Hypertension Medication:
MT is currently taking metoprolol 50 mg twice daily for her uncontrolled hypertension. Metoprolol is a beta-blocker that reduces blood pressure by blocking the action of beta-adrenergic receptors. It is commonly used as a first-line treatment for hypertension, especially in patients with comorbidities such as heart failure or ischemic heart disease. However, its effectiveness as monotherapy in reducing cardiovascular events in the general population has been questioned (Williams et al., 2016).
In the case of MT, her blood pressure remains high (174/94 mmHg) despite taking metoprolol. This suggests inadequate blood pressure control with her current medication regimen. Considering her age, gender, and ethnicity, it is important to select an antihypertensive medication that has demonstrated efficacy in these specific populations.
According to the American College of Cardiology/American Heart Association (ACC/AHA) guidelines for the management of hypertension, thiazide diuretics, calcium channel blockers (CCBs), and angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are recommended as initial therapy for most patients, including those with compelling indications (Whelton et al., 2018). In individuals over 60 years of age, the guidelines further recommend initiating treatment with a thiazide diuretic or CCB (Whelton et al., 2018).
Based on these recommendations, a potential change in medication for MT could involve adding a thiazide diuretic or a CCB to her current therapy with metoprolol. Thiazide diuretics, such as hydrochlorothiazide (HCTZ), exert their antihypertensive effect by promoting diuresis and reducing peripheral vascular resistance. HCTZ at a low dose of 12.5 mg daily has been shown to reduce all-cause mortality, stroke, and myocardial infarction in patients over 60 years of age (Whelton et al., 2018).
Alternatively, a CCB, such as amlodipine or verapamil, could be considered as an add-on therapy. CCBs block the influx of calcium ions into the smooth muscle cells of blood vessels, leading to vasodilation and a reduction in blood pressure. Amlodipine 5 mg daily is a commonly prescribed CCB that has proven efficacy in reducing blood pressure (Whelton et al., 2018).
Dyslipidemia Medication:
MT is currently taking ezetimibe 10 mg daily and garlic for her dyslipidemia. Ezetimibe is a cholesterol absorption inhibitor that reduces low-density lipoprotein (LDL) cholesterol levels by inhibiting its absorption in the intestines. It is typically used as an adjunct therapy to statins or as monotherapy in cases where statins are contraindicated or not tolerated. Garlic, on the other hand, is a dietary supplement that has been suggested to have potential lipid-lowering effects, although the evidence is limited and inconsistent.
MT’s lipid profile reveals a total cholesterol of 240 mg/dL, LDL cholesterol of 163 mg/dL, HDL cholesterol of 41 mg/dL, and triglycerides of 183 mg/dL. According to the ACC/AHA guidelines on the management of blood cholesterol, the primary goal of therapy in patients with clinical atherosclerotic cardiovascular disease (ASCVD) or LDL cholesterol levels ≥190 mg/dL is to achieve an LDL cholesterol reduction of ≥50% (Grundy et al., 2019). In all other patients, including MT, the guidelines suggest a treatment approach based on estimated 10-year ASCVD risk.
In the case of MT, her 10-year ASCVD risk should be calculated using the ACC/AHA Pooled Cohort Equations to determine the intensity of statin therapy recommended (Grundy et al., 2019). The Pooled Cohort Equations estimate the risk of a first ASCVD event (defined as nonfatal myocardial infarction, coronary heart disease death, or fatal or nonfatal stroke) over a 10-year period based on age, gender, race, total cholesterol, HDL cholesterol, systolic blood pressure, use of antihypertensive medication, diabetes status, and smoking status.
Based on MT’s significant family history of CVD and her other risk factors, her estimated 10-year ASCVD risk may be sufficiently high to warrant statin therapy. The appropriate statin intensity can be determined based on the calculated risk, and ezetimibe could be continued as an adjunct therapy if the LDL cholesterol reduction achieved with statin therapy alone is insufficient.